This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Groups

Publications

PD Dr. med. Juliane Walz née Stickel

  2019
  Roerden, M, Walz, JS, Müller, MR, Sökler, M, Federmann, B, Kanz, L, Bethge, W, Vogel, W (2019). The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience. J Cancer Res Clin Oncol [in press].
  Bauer, J, Nelde, A, Bilich, T, Walz, JS (2019). Antigen Targets for the Development of Immunotherapies in Leukemia. Int J Mol Sci. 2019 Mar 20;20(6). 
  Bilich, T*, Nelde, A*, Bichmann, L, Roerden, M, Salih, HR, Kowalewski, DJ, Schuster, H, Tsou, CC, Marcu, A, Neidert, MC, Lübke, M, Rieth, J, Schemionek, M, Brümmendorf, TH, Vucinic, V, Niederwieser, D, Bauer, J, Märklin, M, Peper, JK, Klein, R, Kohlbacher, O, Kanz, L, Rammensee, HG, Stevanović, S, Walz, JS (2019). The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 133(6):550-565.
   
  2018
  Kuželová, K, Brodská, B, Schetelig, J, Röllig, C, Ráčil, Z, Walz, JS, Helbig, G, Fuchs, O, Vraná, M, Pecherková, P, Šálek, C, Mayer, J (2018). Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.. PLoS One 13(12):e0204290.
  Walz, JS, Kowalewski, DJ, Backert, L, Nelde, A, Kohlbacher, O, Weide, B, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S (2018). Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. Leuk Lymphoma 59(8):1949-1958.
  Neidert, MC, Kowalewski, DJ, Silginer, M, Kapolou, K, Backert, L, Freudenmann, LK, Peper, JK, Marcu, A, Wang, SS, Walz, JS, Wolpert, F, Rammensee, HG, Henschler, R, Lamszus, K, Westphal, M, Roth, P, Regli, L, Stevanović, S, Weller, M, Eisele, G (2018). The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol 135(6):923-938.
  Nelde, A, Kowalewski, DJ, Backert, L, Schuster, H, Werner, JO, Klein, R, Kohlbacher, O, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S, Walz, JS (2018). HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy. Oncoimmunology 7(4):e1316438.
  2017
  Maurer, S, Kropp, KN, Klein, G, Steinle, A, Haen, SP, Walz, JS, Hinterleitner, C, Märklin, M, Kopp, HG, Salih, HR (2017). Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology 7(2):e1364827.
  Schuster, H, Peper, JK, Bösmüller, HC, Röhle, K, Backert, L, Bilich, T, Ney, B, Löffler, MW, Kowalewski, DJ, Trautwein, N, Rabsteyn, A, Engler, T, Braun, S, Haen, SP, Walz, JS, Schmid-Horch, B, Brucker, SY, Wallwiener, D, Kohlbacher, O, Fend, F, Rammensee, HG, Stevanović, S, Staebler, A, Wagner, P (2017). The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A 114(46):E9942-E9951.
  Heidenreich, F, Rücker-Braun, E, Walz, JS, Eugster, A, Kühn, D, Dietz, S, Nelde, A, Tunger, A, Wehner, R, Link, CS, Middeke, JM, Stölzel, F, Tonn, T, Stevanovic, S, Rammensee, HG, Bonifacio, E, Bachmann, M, Zeis, M, Ehninger, G, Bornhäuser, M, Schetelig, J, Schmitz, M (2017). Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells. Haematologica 102(11):e460-e464. 
  Liu, X, Pichulik, T, Wolz, OO, Dang, TM, Stutz, A, Dillen, C, Delmiro Garcia, M, Kraus, H, Dickhöfer, S, Daiber, E, Münzenmayer, L, Wahl, S, Rieber, N, Kümmerle-Deschner, J, Yazdi, A, Franz-Wachtel, M, Macek, B, Radsak, M, Vogel, S, Schulte, B, Walz, JS, Hartl, D, Latz, E, Stilgenbauer, S, Grimbacher, B, Miller, L, Brunner, C, Wolz, C, Weber, ANR (2017). Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol 140(4):1054-1067.e10.
  Backert, L, Kowalewski, DJ, Walz, S, Schuster, H, Berlin, C, Neidert, MC, Schmeionek, M, Brümmendorf, TH, Vucinic, V, Niederwieser, D, Kanz, L, Salih, HR, Kohlbacher, O, Weisel, K, Rammensee, HG, Stevanović, S, Walz, JS (2017). A meta-analysis of HLA peptidome composition in different hematological entities: Entity-specific dividing lines and “pan-leukemia” antigens. Oncotarget 8(27): 43915–43924.
  2016
  Nelde, A, Stickel, JS, Kowalewski, DJ, Schuster, H, Wolz, O, Peper, JK, Gloria, YC, Langerak, AW, Muggen, AF, Claus, R, Bonzheim, I, Fend, F, Salih, HR, Kanz, L, Rammensee, H-G, Stevanović, S, Weber, ANR (2016). HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology 2017;6(3):e1219825.
  Kowalewski, DJ, Walz S, Backert L, Schuster H, Kohlbacher O, Weisel K, Rittig SM, Kanz L, Salih HR, Rammensee, HG, Stevanovic, S and Stickel, JS (2016). Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. Blood Cancer J 6: e411.
  Werner JO*, Stickel JS*, M, Droppa, P, Krumm, MR, Müller, L, Kanz, F, Kreth (2016) Pericardial effusion as first manifestation of NSCLC. Ann Hematol Oncol. [In press]. 
  2015
  Walz, S*, Stickel, JS*, Kowalewski, DJ, Schuster, H, Weisel, K, Backert, L, Kahn, S, Nelde, A, Stroh, T, Handel, M, Kohlbacher, O, Kanz, L, Salih, HR, Rammensee, HG, Stevanović, S (2015) The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell based immunotherapy. Blood. 2015 Sep 3;126(10):1203-13.
  Kowalewski, DJ, Stevanovic, S, Rammensee, HG, Stickel, JS (2015) Anti-leukemia T cell responses in CLL – We don’t need no aberration. Oncoimmunology. 2015 Mar 16;4(7).
  Kowalewski, DJ, Schuster, H, Backert, L, Berlin, C, Kahn, S, Kanz, L, Salih, HR, Rammensee, HG, Stevanovic, S, Stickel, JS (2015) HLA ligandome analysis identifies the underlying specificities of spontaneous anti-leukemia immune responses in CLL. Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75.
  Berlin, C, Kowalewski, DJ, Schuster, H, Mirza, N, Walz, S, Handel, M, Schmid-Horch, B, Salih, HR, Kanz, L, Rammensee, HG, Stevanovic, S, & Stickel, JS (2015) Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia. 2015 Mar;29(3):647-59.
  2013
  Stickel, JS, Mayer, F, Vollmer, JP, Zurn, CS, Gawaz, M, Kanz, L, & Bauer, A (2013) Ventricular thrombus and thrombocytopenia as first presentation of anaplastic thyroid carcinoma. J Clin Oncol 31(12):e194-196.
  Seizer, P, Klingel, K, Stickel, J, Dorn, C, Horger, M, Kandolf, R, Bigalke, B, May, AE, Gawaz, M, & Schreieck, J (2013) Left ventricular site-directed biopsy guided by left ventricular voltage mapping: a proof of principle. Int J Cardiol 168(3):3113-3114. 
  2011
  Bolla, D, Wiedemann, N, Ohlschlegel, C, Schoning, A, Stickel, J, Thurlimann, B, & Hornung, R (2011) Pseudoangiomatous stromal hyperplasia of breast in man: a case report. The breast journal 17(3):311-312.
  Stickel, JS, Stickel, N, Hennenlotter, J, Klingel, K, Stenzl, A, Rammensee, HG, & Stevanovic, S (2011) Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation. BMC Urol 11:1. 
  Stickel, JS (2011) Tumorantigene des Nierenzellkarzinoms, Südwest-deutscher Verlag für Hochschulschriften, Book p 224
  2009
  Stickel, JS, Weinzierl, AO, Hillen, N, Drews, O, Schuler, MM, Hennenlotter, J, Wernet, D, Muller, CA, Stenzl, A, Rammensee, HG, & Stevanovic, S (2009) HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother 58(9):1407-1417. 

* These authors contributed equally to this work